SuspendedEUCTR 2014-002765-30
European Long-acting Antipsychotics in Schizofrenia Trial EULAST
This historical record does not confirm current site availability.
Historical research recordMultiple countriesSchizophrenia
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Austria · Belgium and 9 more locations
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Suspended
- Enrollment listed in the registry
- 600
- Sponsor
- EGRIS
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Belgium, Austria, Czechia, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2014-002765-30
- Official title
Show the full official title
European Long-acting Antipsychotics in Schizofrenia Trial EULAST
Recruitment & locations
SuspendedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Austria · Belgium · Czechia
8 more locations
- Denmark
- Greece
- Hungary
- Italy
- Netherlands
- Norway
- Romania
- Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is EGRIS.
Is this study still recruiting?
The historical registry lists this study as suspended.
Want to explore more studies?
Explore studiesRelated studies
A four-week, multicentre, double-blinded, randomised, active- and placebo-controlled, parallel-group trial investigating efficacy and safety of cannabidiol in acute, early-stage schizophrenic patie...
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of MIN-101 in Patients With Negative Symptoms of Schiz...